Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - palbociclib -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - palbociclib -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - palbociclib -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

duopharma hapi sdn. bhd. - palbociclib -

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 100mg - film coated tablet - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide crospovidone opadry green 03k110010 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 125mg - film coated tablet - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 75mg - film coated tablet - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Իսրայել - անգլերեն - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - capsules - palbociclib 125 mg - palbociclib - ibrance is indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with:- an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or- fulvestrant in patients with disease progression following endocrine therapy

Հորդանան - անգլերեն - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - palbociclib 100 mg - 100 mg

Հորդանան - անգլերեն - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - palbociclib 125 mg - 125 mg